Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy Treatment for Metastatic PHEO
2011

New Treatment for Metastatic Pheochromocytoma Using LB1 and Chemotherapy

Sample size: 20 publication 10 minutes Evidence: high

Author Information

Author(s): Lucia Martiniova, Jie Lu, Jeffrey Chiang, Marcelino Bernardo, Russell Lonser, Zhengping Zhuang, Karel Pacak

Primary Institution: National Institutes of Health

Hypothesis

Can the combination of LB1 and temozolomide enhance the efficacy of chemotherapy against metastatic pheochromocytoma?

Conclusion

The combination of LB1 and temozolomide significantly improved survival rates and tumor-free outcomes in a mouse model of metastatic pheochromocytoma.

Supporting Evidence

  • The combination treatment resulted in long-term disease-free survival of up to 40% of animals.
  • Inhibition of PP2A was associated with prevention of G1/S phase arrest by p53.
  • The study showed that LB1 enhances the efficacy of temozolomide against metastatic PHEO.

Takeaway

Researchers found that using a new drug called LB1 with a common cancer treatment helped mice with a tough type of cancer live longer and stay tumor-free.

Methodology

The study evaluated the effects of LB1 and temozolomide on a PHEO cell line in vitro and in a mouse model in vivo.

Limitations

The study was conducted in a mouse model, which may not fully replicate human responses.

Participant Demographics

Female athymic nude mice aged 6-10 weeks were used in the study.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1371/journal.pone.0014678

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication